In Q3 of fiscal 2019, the quarter ended Oct 31, 2018, Betterlife Pharma Inc. used $705,895 of cash from operations, down 633.9% from the same quarter a year earlier.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Oct 31, 2018
|
Q3 FY2019
Oct 31, 2018
|
Q2 FY2019 YTD
Jul 31, 2018
|
Q4 FY2018
Jan 31, 2018
|
Q3 FY2018
Oct 31, 2017
|
Q2 FY2018
Jul 31, 2017
|
Q1 FY2018
Apr 30, 2017
|
Q4 FY2017
Jan 31, 2017
|
Q3 FY2017
Oct 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||
| Stock-based compensation |
—
|
—
|
—
|
—
|
—
|
—
|
0
-100.0%
|
5
|
4
|
| Operating cash flow |
-4
-1154.9%
|
-1
-633.9%
|
-3
-7306.5%
|
-0
-96.6%
|
-0
+33.8%
|
-0
-9.3%
|
-0
+18.1%
|
-0
|
-0
|
| Investing | |||||||||
| Investing cash flow |
—
|
-0
|
-0
|
—
|
—
|
—
|
—
|
—
|
—
|
| Financing | |||||||||
| Debt issued |
—
|
—
|
—
|
—
|
0
|
—
|
—
|
—
|
—
|
| Debt repaid |
—
|
0
|
0
|
—
|
—
|
—
|
—
|
—
|
—
|
| Financing cash flow |
5
+1293.1%
|
1
+225.1%
|
4
+198.4%
|
0
+1808.0%
|
0
-11.8%
|
-4
-51957.3%
|
—
|
-0
|
0
|
| Ratios | |||||||||
| Cash conversion |
—
|
—
|
—
|
—
|
-0.18x
|
—
|
—
|
—
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BETRF (OTC)
- Fiscal year ends
- January 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1464165
- Former names
- Pivot Pharmaceuticals Inc. (until Dec 3, 2019); Neurokine Pharmaceuticals Inc. (until Mar 26, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.